Response

Affiliations

¹ Department of Radiation Oncology, University of Illinois at Chicago, Chicago, IL (MK, RRW); Department of Radiation and Cellular Oncology, The University of Chicago, Chicago, IL (MK, RM, RRW); Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX (UM); Department of Radiation Oncology, Yale University, New Haven, CT (ZH); Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX (DJS). mkoshy@radonc.uchicago.edu.
² Department of Radiation Oncology, University of Illinois at Chicago, Chicago, IL (MK, RRW); Department of Radiation and Cellular Oncology, The University of Chicago, Chicago, IL (MK, RM, RRW); Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX (UM); Department of Radiation Oncology, Yale University, New Haven, CT (ZH); Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX (DJS).

Comment

Matthew Koshy et al. J Natl Cancer Inst. 2016.

. 2016 Jan 7;108(3):djv413.

doi: 10.1093/jnci/djv413. Print 2016 Mar.

¹ Department of Radiation Oncology, University of Illinois at Chicago, Chicago, IL (MK, RRW); Department of Radiation and Cellular Oncology, The University of Chicago, Chicago, IL (MK, RM, RRW); Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX (UM); Department of Radiation Oncology, Yale University, New Haven, CT (ZH); Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX (DJS). mkoshy@radonc.uchicago.edu.
² Department of Radiation Oncology, University of Illinois at Chicago, Chicago, IL (MK, RRW); Department of Radiation and Cellular Oncology, The University of Chicago, Chicago, IL (MK, RM, RRW); Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX (UM); Department of Radiation Oncology, Yale University, New Haven, CT (ZH); Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX (DJS).

No abstract available

Comment on

Prevalence and Predictors of Inappropriate Delivery of Palliative Thoracic Radiotherapy for Metastatic Lung Cancer.
Koshy M, Malik R, Mahmood U, Husain Z, Weichselbaum RR, Sher DJ. Koshy M, et al. J Natl Cancer Inst. 2015 Sep 30;107(12):djv278. doi: 10.1093/jnci/djv278. Print 2015 Dec. J Natl Cancer Inst. 2015. PMID: 26424779 Free PMC article.
RE: Prevalence and Predictors of Inappropriate Delivery of Palliative Thoracic Radiotherapy for Metastatic Lung Cancer.
Schild SE, Ashman JB, Keole SR, Daniels TB, Rule WG. Schild SE, et al. J Natl Cancer Inst. 2016 Jan 7;108(3):djv412. doi: 10.1093/jnci/djv412. Print 2016 Mar. J Natl Cancer Inst. 2016. PMID: 26744478 No abstract available.